menu
    • menu
    [{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bright Peak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Bright Peak Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bright Peak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"Programmed cell death protein 1 (PD-1)","graph1":"Oncology","graph2":"Phase I","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bright Peak Therapeutics \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Bright Peak Therapeutics \/ Bright Peak Therapeutics"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Bright Peak Therapeutics

    Menu

    Bright Peak Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPT567

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

                            Details : BPT567 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 17, 2025

                            Lead Product(s) : BPT567

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPT567

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bright Peak Doses First Patient in Phase 1/2a Trial of BPT567 Immunoconjugate

                            Details : BPT567, is a bifunctional PD1-IL18 immunoconjugate aimed at activating and enhancing immune responses directly within the tumor microenvironment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2024

                            Lead Product(s) : BPT567

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPT567

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Johnson & Johnson

                            Deal Size : $90.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics Announces $90 Million in Series C Financing for PD1-IL18

                            Details : The proceeds from the Series C financing will be used to advance the Bright Peak Therapeutics lead product BPT567 into a clinical trial for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 11, 2024

                            Lead Product(s) : BPT567

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Johnson & Johnson

                            Deal Size : $90.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPT-143

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AAC...

                            Details : BPT-143, full-length, folded and PEGylated protein demonstrated power of protein synthesis platform to engineer pleiotropic native cytokines into optimized therapeutics and exploiting technology to develop pipeline of novel designer cytokines and multi-m...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 04, 2022

                            Lead Product(s) : BPT-143

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LZM009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Livzon Pharmaceutical Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targete...

                            Details : Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the g...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 16, 2021

                            Lead Product(s) : LZM009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Livzon Pharmaceutical Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPT-143

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : RA Capital Management

                            Deal Size : $107.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

                            Details : BPT-143 is an enhanced, half-life extended, IL-2 cytokine that uses small modifications to amino acid side chains to block binding to IL-2 receptor alpha, and enhance binding to IL-2 receptor beta.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 10, 2021

                            Lead Product(s) : BPT-143

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : RA Capital Management

                            Deal Size : $107.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Ajinomoto Bio-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bright Peak Therapeutics and Ajinomoto Enter into a Research Collaboration and License Agreement to Create Nov...

                            Details : As part of the collaboration and license agreement with Ajinomoto Co., the AJICAP® technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 25, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Ajinomoto Bio-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed

                            Bright Peak Therapeutics

                            Switzerland arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Ridgeline Therapeutics Discovery

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Versant Ventures Launches Bright Peak Therapeutics

                            Details : Bright Peak’s technology platform allows a wide range of proteins to be chemically assembled de novo. The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therap...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 28, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Ridgeline Therapeutics Discovery

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth